Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Advanced Symptom Management in Multiple Sclerosis.

Crabtree-Hartman E.

Neurol Clin. 2018 Feb;36(1):197-218. doi: 10.1016/j.ncl.2017.08.015. Review.

PMID:
29157400
2.

Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.

Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11. Erratum in: Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8943.

3.

Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.

Block VJ, Lizée A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Tremblay M, Gourraud PA, Ng MY, Pletcher MJ, Olgin JE, Marcus GM, Allen DD, Cree BA, Gelfand JM.

J Neurol. 2017 Feb;264(2):316-326. doi: 10.1007/s00415-016-8334-6. Epub 2016 Nov 28.

4.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

5.

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.

Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS.

JAMA Neurol. 2016 Jul 1;73(7):790-4. doi: 10.1001/jamaneurol.2016.0826.

PMID:
27135594
6.

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.

Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076. eCollection 2015 Jun.

7.

Precision medicine in chronic disease management: The multiple sclerosis BioScreen.

Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL.

Ann Neurol. 2014 Nov;76(5):633-42. doi: 10.1002/ana.24282. Epub 2014 Oct 14. Review.

8.

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E.

PLoS One. 2011 Feb 3;6(2):e16664. doi: 10.1371/journal.pone.0016664.

9.

Sex differences in multiple sclerosis.

Crabtree-Hartman E.

Continuum (Minneap Minn). 2010 Oct;16(5 Multiple Sclerosis):193-210. doi: 10.1212/01.CON.0000389942.81981.72.

PMID:
22810606
10.

Atypical cerebral laterality in adults with persistent developmental stuttering.

Foundas AL, Corey DM, Angeles V, Bollich AM, Crabtree-Hartman E, Heilman KM.

Neurology. 2003 Nov 25;61(10):1378-85.

PMID:
14638959

Supplemental Content

Loading ...
Support Center